Biotech News

Targeting underlying causes of neurodegenerative diseases | 2026 Bloom Burton & Co. Healthcare Investor Conference

ProMIS Neurosciences (PMN)ProMIS Neurosciences2026-04-27 10:30 ESTClinical readout

Home

About Us Overview

Management Team

Board of Directors

Scientific Advisory Board

Clinical Advisory Board

Our Science

Product Pipeline Overview

PMN310 | Amyloid-Beta

PMN267 | TDP-43

PMN442 | Alpha-Synuclein

Vaccines

Posters & Publications

Clinical Trials

Investors Overview

News & Events

Company Info

Financial Results

Stock Data

SEDAR

SEC Filings

Governance

Contact

Press Releases

Investors Investors

Overview

News & Events Overview

Press Releases

IR Calendar

Email Alerts

Company Info Overview

Management Team

Presentations

Contacts

FAQ

Financial Results

Stock Data NASDAQ: PMN

Analyst Coverage

SEDAR

SEC Filings

Governance Overview

Board of Directors

Board Committees

Governance Documents

Email Alerts

Contacts

Open original release

Related news

PMNProMIS Neurosciences2026-07-14 12:00 EST

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

PMNProMIS Neurosciences2026-05-28 10:13 EST

ProMIS Neurosciences to Participate in Upcoming Conferences in June

PMNProMIS Neurosciences2026-05-12 06:30 EST

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

PMNProMIS Neurosciences2026-03-25 08:00 EST

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

PMNProMIS Neurosciences2026-03-19 16:00 EST

BriefGlance.com: ProMIS Unveils Precision Vaccines for ALS and Parkinson's Disease

GSKGSK plc2026-07-15 13:40 EST

GSK completes acquisition of Nuvalent, Inc.

TNXPTonix Pharmaceuticals2026-07-15 13:05 EST

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

MRKMerck2026-07-15 12:31 EST

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

MRKMerck2026-07-15 12:31 EST

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

LIXTLixte Biotechnology Holdings2026-07-15 12:30 EST

NOMAD Power Solutions Strengthens Subsidiary Executive Leadership

View all latest news

ProMIS Neurosciences

ProMIS Neurosciences is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

PMNGSK plc2026-07-15 13:40 EST

GSK completes acquisition of Nuvalent, Inc.

PMNMerck2026-07-15 12:31 EST

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

PMNMerck2026-07-15 12:31 EST

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

PMNAlnylam Pharmaceuticals, Inc.2026-07-15 12:00 EST

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurologi

PMNBruker2026-07-15 11:00 EST

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

Stock data

Close: 12.80 USD
Market cap: 127.79M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States